ALC.SW Alcon down 2.39% pre-market 04 Feb 2026: CHF60.48 near 50d support

Pre-market trading shows ALC.SW stock at CHF60.48, down 2.39% on 04 Feb 2026 as volume runs above average. The move follows mixed sector cues and a product launch, and leaves the price close to the 50-day average CHF63.37. We note PE 37.33 and EPS 1.62, which frame valuation questions ahead of the next earnings date. This pre-market snapshot matters for most-active traders on the SIX in Switzerland and for portfolio managers tracking healthcare names.

ALC.SW stock price action and liquidity

ALC.SW stock opened CHF62.00 and trades at CHF60.48 pre-market, a CHF1.48 decline from the prior close of CHF61.96. Intraday range shows day low CHF60.24 and day high CHF62.10, with volume at 1,477,130 versus average 1,155,351, signalling above-average activity. This liquidity makes ALC.SW one of the most active Swiss healthcare names this session on the SIX.

News drivers and recent ALC.SW stock updates

Alcon announced a Canadian launch of the PRECISION7 weekly contact lens, a product update that can affect vision-care sales mix and near-term growth source. The product push complements Alcon’s global portfolio listed at the company site and may help offset surgical cyclicality source.

ALC.SW stock fundamentals and valuation

Alcon trades at PE 37.33 with EPS 1.62 and market cap about CHF29.91B. Key ratios show price-to-book 1.74, free cash flow yield 4.12%, and debt-to-equity 0.24, which underline moderate leverage and positive cash generation. One clear metric: book value per share is CHF44.74, giving investors a tangible book cushion against share volatility.

Technicals, sector context and Meyka AI grade for ALC.SW stock

Technicals show RSI 58.62 and the stock sitting below the 50-day average CHF63.37 and the 200-day average CHF66.51, suggesting short-term resistance. The Swiss healthcare sector average PE is 34.55, so Alcon’s valuation at 37.33 is slightly above peers. Meyka AI rates ALC.SW with a score out of 100: 70.96 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst signals. These grades are model outputs and not guaranteed; we are not financial advisors.

ALC.SW stock forecasts and price target scenarios

Meyka AI’s forecast model projects monthly CHF59.57, quarterly CHF61.27, and yearly CHF58.39 for ALC.SW stock. Against the current CHF60.48, the 12-month model projection implies a -3.45% downside. For scenario planning we suggest a near-term tactical target of CHF63.00 and a 12-month target range CHF68.00–CHF75.00 depending on surgical volume recovery and vision-care trends.

Risks, opportunities and trading considerations for ALC.SW stock

Opportunities include product rollouts and margin recovery in surgical equipment sales, plus steady contact-lens demand. Risks are valuation sensitivity given the PE 37.33, inventory days near 194, and cyclical surgical demand. Traders should watch the next earnings date 24 Feb 2026 and monitor order flow, as higher-than-average volume can accelerate directional moves on the SIX.

Final Thoughts

ALC.SW stock opens pre-market at CHF60.48, down 2.39%, and sits close to its 50-day average, making short-term support and the upcoming earnings release key catalysts. Meyka AI’s forecast model projects yearly CHF58.39, implying -3.45% versus the current price; forecasts are model-based projections and not guarantees. Our Meyka grade of B+ (70.96) balances solid cash generation, moderate debt, and growth from product launches against a premium PE and surgical cyclicality. For most-active traders on the SIX, a tactical trade towards CHF63.00 can capture a bounce if momentum returns, while longer-term investors should track surgical backlog data and contact-lens growth to justify a CHF68.00–CHF75.00 12-month target. For a live dashboard and deeper metric drill-down see our platform Meyka AI stock page for ALC.SW. Remember forecasts are model outputs and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.